

Andrew M. Solomon

OF COUNSEL

he / him / his

St. Louis, MO | 314.622.6132

asolomon@polsinelli.com



Andrew (Andy) Solomon utilizes his 35+ years of diversified experiences to provide clients in the life sciences and chemical industries the opportunity to achieve an appropriate return on their investment. Andy has spent the majority of his career as an in-house practitioner, handling both intellectual property and commercial matters and utilizes his in-house experience to deliver advice in a straightforward, pragmatic, business-sensitive way. He retired from the Perrigo Company, a leading global generic, store brand and value brand pharmaceutical company, in 2017 and is a registered patent attorney with a chemical background.

Andy's practice focuses on:

- Comprehensive intellectual property, regulatory, and commercial strategies to enable the timely launch of pharmaceutical products
- Intellectual property litigation and inter partes proceedings
- Intellectual property and regulatory counseling and portfolio development
- Freedom to operate patent opinions
- Complex licensing agreements
- Commercial agreements
- Transactional due diligence and agreements
- Litigation settlement agreements

Specific areas of focus include:

- Hatch Waxman intellectual property and regulatory issues
- Regulatory approval of pharmaceuticals
- Review of product labeling for regulatory compliance
- Acquisitions and divestitures of life science and chemical companies
- Product development, licensing, distribution and supply agreements
- Generic, store brand and value brand marketing
- Formal client education

Education

- University of Missouri-Columbia School of Law (J.D., 1985)

Capabilities

- Animal Health
- Chemical Manufacturing
- Hatch-Waxman & Biologics
- Intellectual Property
- Intellectual Property Counseling & Opinions
- Intellectual Property Litigation
- Licensing & Transactions
- Life Sciences
- Patent Litigation
- Technology
- Agribusiness

- University of Missouri-Columbia (B.S., 1982)
 - Chemical Engineering

Bar Admissions

- Missouri, 2018
- Illinois, 1990
- Pennsylvania, 1985

Recognition

- Selected for inclusion in *Best Lawyers in America*® for Litigation - Intellectual Property, 2025-2026

Matters

- In house management of more than 50 Hatch Waxman patent infringement lawsuits resulting in multiple trial and appeals court victories and favorable settlements.
- Management of unfair competition litigation resulting in a jury verdict allowing the continued use of a comparison statement.
- Participation as both lead commercial attorney and lead intellectual property attorney on multiple transactional matters having a positive fiscal impact on corporate earnings, including acquisitions, divestitures, and collaboration agreements.
- Review of advertising, press releases and promotional materials for regulatory and legal compliance.
- Drafting and issuing over 150 original patents across a diverse range of technologies including biochemical, chemical and mechanical. Prepare and register over 50 original trademarks and numerous copyrights.
- Present seminars on a wide array of topics, including litigation from an in-house perspective, intellectual property, trade secrets and confidentiality, contracts, antitrust, compliance, advertising, regulatory law and document creation (paper and electronic).

Publications

April 29, 2026

How Skinny is Skinny Enough? Takeaways from the SCOTUS Oral Argument in the Amarin/Hikma Case

July 14, 2025

Device Patents in the Orange Book: May 21, 2025, FTC Warning Letters Appear to have Minimal Impact

May 23, 2025

Orange Book Listings: Republican Led FTC Picks Up Where Democrat Led FTC Left Off

April 24, 2025

Drug Pricing and Payment Executive Order Shows Trump Administration's Cards

March 5, 2025

Federal Circuit Refuses to Rehear Case Involving Orange Book Listing of Device Patents

January 23, 2025

Court Ruling Alters the Calculus for Orange Book Patent Listings

Co-Author, Life Science Leader

December 23, 2024

Federal Circuit Decides Case Involving Orange Book Listing of Device Patents

July 17, 2024

The FTC's Challenge to the Listing of Device Patents in the Orange Book: What Challenge?